Isao Teshirogi

Japan's Shionogi bucks the pharma trend with focus on old, cheap drugs

Dartmouth Institute Steven Woloshin

What does 'breakthrough' mean to docs and consumers? It's not the FDA defin

stop sign

Orexigen puts Contrave at risk by stopping yet another heart study

laptop against white background

As promised, we bring you the new and improved FiercePharma

Many of you saw the new FierceBiotech website launch earlier this week and now I am pleased to bring you the newly redesigned FiercePharma.  Our new website …

Januvia box

Merck's DPP-4 newcomer Marizev trails Januvia in safety: Report

Merck wants its new weekly diabetes treatment, Marizev, to build on the success of its blockbuster DPP-4 inhibitor Januvia. But at least when it comes to…


AbbVie, Roche look for blockbuster boost from $110K leukemia med

There's a new leukemia drug in town, and to hear analysts tell it, Venclexta is destined to hit the blockbuster target. Developers AbbVie and Roche say…

New Merck KGaA logo in front of company building

Merck KGaA loses FDA nod for fertility drug

Merck KGaA launched fertility med Luveris more than 10 years ago, but never conducted a follow-up trial required by the FDA. Now, the agency has pulled its…

pointing finger generic art

Amid finger-pointing on native ad rules, pharma gears up to do it right

Pharma needs to set its guidelines for native advertising now, experts advise, after a new study called out marketers for breaking FTC rules on labeling paid…


In Shkreli's wake, KaloBios vows fair pricing. Will others follow?

KaloBios made waves last week with a vow to price drugs fairly. Should the rest of pharma follow suit with their own oaths?


Pharma primed to invest in services, but will patients get the message?

Pharma can no longer treat patient services as an add-on. They're a must-have, a new Accenture report says, and drugmakers are putting their money into…

Joe Biden

Can the cancer moonshot help cure Big Pharma's big bad reputation?

Vice President Joe Biden's cancer moonshot initiative has been celebrated for its exuberance and chided for its too-small budget. But InTouch Solutions…


Allergan gets Linzess marketing edge from Ironwood exec

When Tom McCourt, chief commercial officer at Ironwood Pharmaceuticals, first met with company R&D chief Mark Currie, he had a critical question about up-…

Humira "Crohn's Disease: Control"

AbbVie's Humira, GSK's Breo top March TV spenders

Humira is refusing to go quietly. Even as the anti-inflammatory faces patent expiration in the U.S. later this year, AbbVie continues not only an aggressive…